Determining the factors affecting bortezomib’s adverse events in the treatment of newly diagnosed multiple myeloma
This observational study shows that bortezomib applied via SC injection had a lower incidence of peripheral neuropathy, infection, and dyspepsia when compared to IV injection. Patients with DS stage III had higher peripheral neuropathy adverse reactions than patients with stage I. The patients with reduced dose of bortezomib were associated with increased infection in MM patients.
Authors
- Xiaoyan Han (ORCID: https://orcid.org/0009-0004-8881-4523)
- Jingsong He (ORCID: https://orcid.org/0000-0002-1190-1037)
- Zhen Cai (ORCID: https://orcid.org/0000-0001-6026-3804)
- Gaofeng Zheng
- Mengmeng Dong (ORCID: https://orcid.org/0000-0001-7353-8109)
- Yang Li (ORCID: https://orcid.org/0000-0002-0112-1328)
Institutions
- Zhejiang University (CN)
Publication Details
- Journal
- Hematology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1080/16078454.2025.2548069
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province